124 related articles for article (PubMed ID: 34446805)
1. Establishing standardized immune phenotyping of metastatic melanoma by digital pathology.
Sobottka B; Nowak M; Frei AL; Haberecker M; Merki S; ; Levesque MP; Dummer R; Moch H; Koelzer VH
Lab Invest; 2021 Dec; 101(12):1561-1570. PubMed ID: 34446805
[TBL] [Abstract][Full Text] [Related]
2. Detailed spatial immunophenotyping of primary melanomas reveals immune cell subpopulations associated with patient outcome.
Attrill GH; Lee H; Tasker AT; Adegoke NA; Ferguson AL; da Silva IP; Saw RPM; Thompson JF; Palendira U; Long GV; Ferguson PM; Scolyer RA; Wilmott JS
Front Immunol; 2022; 13():979993. PubMed ID: 36003398
[TBL] [Abstract][Full Text] [Related]
3. Digital Immunophenotyping Predicts Disease Free and Overall Survival in Early Stage Melanoma Patients.
De Logu F; Galli F; Nassini R; Ugolini F; Simi S; Cossa M; Miracco C; Gianatti A; De Giorgi V; Rulli E; Cossu A; Massi D; Mandalà M
Cells; 2021 Feb; 10(2):. PubMed ID: 33671367
[TBL] [Abstract][Full Text] [Related]
4. Defining Melanoma Immune Biomarkers-Desert, Excluded, and Inflamed Subtypes-Using a Gene Expression Classifier Reflecting Intratumoral Immune Response and Stromal Patterns.
Mlynska A; Gibavičienė J; Kutanovaitė O; Senkus L; Mažeikaitė J; Kerševičiūtė I; Maskoliūnaitė V; Rupeikaitė N; Sabaliauskaitė R; Gaiževska J; Suveizdė K; Kraśko JA; Dobrovolskienė N; Paberalė E; Žymantaitė E; Pašukonienė V
Biomolecules; 2024 Jan; 14(2):. PubMed ID: 38397409
[TBL] [Abstract][Full Text] [Related]
5. Dendritic Cell Vaccination in Metastatic Melanoma Turns "Non-T Cell Inflamed" Into "T-Cell Inflamed" Tumors.
Bulgarelli J; Tazzari M; Granato AM; Ridolfi L; Maiocchi S; de Rosa F; Petrini M; Pancisi E; Gentili G; Vergani B; Piccinini F; Carbonaro A; Leone BE; Foschi G; Ancarani V; Framarini M; Guidoboni M
Front Immunol; 2019; 10():2353. PubMed ID: 31649669
[TBL] [Abstract][Full Text] [Related]
6. Measuring multiple parameters of CD8+ tumor-infiltrating lymphocytes in human cancers by image analysis.
Steele KE; Tan TH; Korn R; Dacosta K; Brown C; Kuziora M; Zimmermann J; Laffin B; Widmaier M; Rognoni L; Cardenes R; Schneider K; Boutrin A; Martin P; Zha J; Wiestler T
J Immunother Cancer; 2018 Mar; 6(1):20. PubMed ID: 29510739
[TBL] [Abstract][Full Text] [Related]
7. Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma.
Erdag G; Schaefer JT; Smolkin ME; Deacon DH; Shea SM; Dengel LT; Patterson JW; Slingluff CL
Cancer Res; 2012 Mar; 72(5):1070-80. PubMed ID: 22266112
[TBL] [Abstract][Full Text] [Related]
8. The role of tumor-infiltrating lymphocytes (TILs) as a predictive biomarker of response to anti-PD1 therapy in patients with metastatic non-small cell lung cancer or metastatic melanoma.
Uryvaev A; Passhak M; Hershkovits D; Sabo E; Bar-Sela G
Med Oncol; 2018 Jan; 35(3):25. PubMed ID: 29388007
[TBL] [Abstract][Full Text] [Related]
9. Quantitative Whole Slide Assessment of Tumor-Infiltrating CD8-Positive Lymphocytes in ER-Positive Breast Cancer in Relation to Clinical Outcome.
Krijgsman D; van Leeuwen MB; van der Ven J; Almeida V; Vlutters R; Halter D; Kuppen PJK; van de Velde CJH; Wimberger-Friedl R
IEEE J Biomed Health Inform; 2021 Feb; 25(2):381-392. PubMed ID: 32750943
[TBL] [Abstract][Full Text] [Related]
10. The heterogeneity of tumor-infiltrating CD8+ T cells in metastatic melanoma distorts their quantification: how to manage heterogeneity?
Obeid JM; Hu Y; Erdag G; Leick KM; Slingluff CL
Melanoma Res; 2017 Jun; 27(3):211-217. PubMed ID: 28118270
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic significance of intratumoral CD8+ tumor-infiltrating lymphocytes in medullary carcinoma.
Igari F; Sato E; Horimoto Y; Takahashi Y; Isomura T; Arakawa A; Kitano S; Saito M
Hum Pathol; 2017 Dec; 70():129-138. PubMed ID: 29122657
[TBL] [Abstract][Full Text] [Related]
12. The Prognostic Value of FoxP3+ Tumour-Infiltrating Lymphocytes in Rectal Cancer Depends on Immune Phenotypes Defined by CD8+ Cytotoxic T Cell Density.
Schnellhardt S; Hirneth J; Büttner-Herold M; Daniel C; Haderlein M; Hartmann A; Fietkau R; Distel L
Front Immunol; 2022; 13():781222. PubMed ID: 35140715
[TBL] [Abstract][Full Text] [Related]
13. Response to ipilimumab therapy in metastatic melanoma patients: potential relevance of CTLA-4
Mastracci L; Fontana V; Queirolo P; Carosio R; Grillo F; Morabito A; Banelli B; Tanda E; Boutros A; Dozin B; Gualco M; Salvi S; Romani M; Spagnolo F; Poggi A; Pistillo MP
Cancer Immunol Immunother; 2020 Apr; 69(4):653-662. PubMed ID: 32025849
[TBL] [Abstract][Full Text] [Related]
14. uPAR
Porcelli L; Guida M; De Summa S; Di Fonte R; De Risi I; Garofoli M; Caputo M; Negri A; Strippoli S; Serratì S; Azzariti A
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33972390
[TBL] [Abstract][Full Text] [Related]
15. Tumor-immune landscape patterns before and after chemoradiation in resectable esophageal adenocarcinomas.
Soeratram TT; Creemers A; Meijer SL; de Boer OJ; Vos W; Hooijer GK; van Berge Henegouwen MI; Hulshof MC; Bergman JJ; Lei M; Bijlsma MF; Ylstra B; van Grieken NC; van Laarhoven HW
J Pathol; 2022 Mar; 256(3):282-296. PubMed ID: 34743329
[TBL] [Abstract][Full Text] [Related]
16. Peritumoral Immune Infiltrate as a Prognostic Biomarker in Thin Melanoma.
Sabbatino F; Scognamiglio G; Liguori L; Marra A; Anniciello AM; Polcaro G; Dal Col J; Caputo A; Peluso AL; Botti G; Zeppa P; Ferrone S; Pepe S
Front Immunol; 2020; 11():561390. PubMed ID: 33117345
[TBL] [Abstract][Full Text] [Related]
17. Examining the Relationship between Circulating CD4- CD8- Double-Negative T Cells and Outcomes of Immuno-Checkpoint Inhibitor Therapy-Looking for Biomarkers and Therapeutic Targets in Metastatic Melanoma.
Strippoli S; Fanizzi A; Negri A; Quaresmini D; Nardone A; Armenio A; Sciacovelli AM; Massafra R; De Risi I; De Tullio G; Albano A; Guida M
Cells; 2021 Feb; 10(2):. PubMed ID: 33669266
[TBL] [Abstract][Full Text] [Related]
18. Multiplex immunohistochemistry accurately defines the immune context of metastatic melanoma.
Halse H; Colebatch AJ; Petrone P; Henderson MA; Mills JK; Snow H; Westwood JA; Sandhu S; Raleigh JM; Behren A; Cebon J; Darcy PK; Kershaw MH; McArthur GA; Gyorki DE; Neeson PJ
Sci Rep; 2018 Jul; 8(1):11158. PubMed ID: 30042403
[TBL] [Abstract][Full Text] [Related]
19. Characterization of the Microenvironment in Positive and Negative Sentinel Lymph Nodes from Melanoma Patients.
Messaoudene M; Périer A; Fregni G; Neves E; Zitvogel L; Cremer I; Chanal J; Sastre-Garau X; Deschamps L; Marinho E; Larousserie F; Maubec E; Avril MF; Caignard A
PLoS One; 2015; 10(7):e0133363. PubMed ID: 26218530
[TBL] [Abstract][Full Text] [Related]
20. Early disappearance of tumor antigen-reactive T cells from peripheral blood correlates with superior clinical outcomes in melanoma under anti-PD-1 therapy.
Bochem J; Zelba H; Spreuer J; Amaral T; Wagner NB; Gaissler A; Pop OT; Thiel K; Yurttas C; Soffel D; Forchhammer S; Sinnberg T; Niessner H; Meier F; Terheyden P; Königsrainer A; Garbe C; Flatz L; Pawelec G; Eigentler TK; Löffler MW; Weide B; Wistuba-Hamprecht K
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34933966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
